Acadia Pharmaceuticals intends to again request that oral Nuplazid (pimavanserin) be approved to treat hallucinations and delusions, but this time only when associated with the dementia-related psychosis of Alzheimer’s disease. Its planned request to the U.S. Food and Drug Administration (FDA), in the form of a resubmitted supplemental new drug application (sNDA), follows the FDA’s rejection last year of Nuplazid in treating hallucinations and delusions in a much broader category of dementia-related psychosis. The FDA, in its response letter,…
You must be logged in to read/download the full post.
The post FDA Approval Again Wanted for Nuplazid in Easing Psychosis appeared first on BioNewsFeeds.